Tumor PD-L1 is the only currently approved biomarker (8, 9), and has also demonstrated association with the development of oligoprogression under IO (10), as well as irAE (5), but these associations are weak and complicated by considerable spatial heterogeneity of PD-L1 expression (11). Here, CD274 is linked to neoplasm.